



03-21-07

IFW

1617

PATENT

Attorney Docket No.: IMARX1100-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Unger et al. Art Unit: 1617
Application No.: 09/218,660 Examiner: Layla Soroush
Filing Date: December 22, 1998 Confirmation No. 2775
Title: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND
THERAPEUTIC USE

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

The undersigned, attorney of record for Petitioners, IMARX PHARMACEUTICAL CORP., represents that Petitioners are the Assignees of an undivided interest in Application No. 09/218,660, filed December 22, 1998, entitled NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE as evidenced by the Assignment recorded in the United States Patent and Trademark Office on January 27, 1999, at Reel 09722, Frame 0292.

The evidentiary documents referred to herein have been reviewed by the undersigned and it is certified that to the best of the undersigned's knowledge and belief, title is in the Assignee.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" LABEL NUMBER **EV 876 964 372 US** DATE OF DEPOSIT**March 19, 2007**

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Joshua Gibbs

(TYPED OR PRINTED NAME OF PERSON MAILING PAPER)

(SIGNATURE OF PERSON MAILING PAPER OR FEE)

In the Application of:

Unger et al.

Application No.: 09/218,660

Filed: December 22, 1998

Page 2

PATENT

Attorney Docket No.: IMARX1100-3

Pursuant to 37 C.F.R. § 1.321(c), the undersigned, on behalf of Petitioners, IMARX PHARMACEUTICAL CORP., disclaims the terminal part of any patent granted on the above-identified Application No. 09/218,660 that would extend beyond the expiration date of U.S. Patent No. 6,521,211. Petitioner hereby agrees that any patent so granted on the above-identified application, No. 09/218,660, shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,521,211, this Agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successor or assigns.

Pursuant to 37 C.F.R. § 1.321(c), the undersigned, on behalf of Petitioners, IMARX PHARMACEUTICAL CORP. disclaims the terminal part of any patent granted on the above-identified Application No. 09/218,660 that would extend beyond the expiration date of any patent granted on U.S. Application No. 10/341,167. Petitioner hereby agrees that any patent so granted on the above-identified application, No. 09/218,660, shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent granted on U.S. Application No. 10/341,167, this Agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successor or assigns.

In the Application of:

Unger et al.

Application No.: 09/218,660

Filed: December 22, 1998

Page 3

PATENT

Attorney Docket No.: IMARX1100-3

Check number 585111 in the amount of \$65.00 is enclosed as payment for Terminal Disclaimer fee. No other fee is believed to be due in connection with the filing of this paper. However, the Commissioner is hereby authorized to charge any other fees associated with the filing submitted herewith, or credit any overpayments to Deposit Account No. 07-1896 referencing the above-identified attorney docket number. A duplicate copy of the Transmittal sheet is enclosed.

Respectfully submitted,

Date: March 19, 2007



Victor Repkin

Attorney for Applicants

Registration No. 45,039

Telephone: (858) 638-6664

Facsimile: (858) 677-1465

DLA PIPER US LLP

4365 Executive Drive, Suite 1100

San Diego, California 92121-2133

USPTO Customer Number 28213